Thrombotic Thrombocytopenic Purpura News and Research

RSS

Promising nanobodies against COVID-19 produced by llamas

News-Medical speaks to Dr. David Brody about his latest research that involved discovering nanobodies produced by llamas that could help combat coronavirus.

25 Jan 2021

Scientists isolate anti-COVID-19 nanobodies produced by a llama

National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or "nanobodies," against SARS-CoV-2 that were produced by a llama named Cormac.

22 Dec 2020

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.

7 Dec 2020

Nanobodies: unharnessed potential in COVID-19 treatment

A new study published in the Journal of Biomolecular Structure and Dynamics in October 2020 discusses the use of nanobodies in diagnosing and treating this deadly disease.

16 Nov 2020

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Canadian researchers from McMaster University, Ontario, have pinpointed platelet activating immune complexes in coagulation disorders associated with coronavirus disease 2019 (COVID-19), the condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2020

Acute kidney injury on the rise in hospitalized pregnant women

A study presented at ASN Kidney Week 2019 (November 5 to November 10) shows that the rate of acute kidney injury (AKI) is rising among US women who are hospitalized in pregnancy. The highest risk is in pregnant diabetic women. Women who suffer acute damage to the kidney while pregnant have 260 times the risk of death while in hospital compared to other pregnant women, at 2.6% vs 0.01%. Both mother and baby are at risk of increased illness and death if the woman has kidney injury during pregnancy.

11 Nov 2019

Researchers find synergistic connection between two deadly blood-clotting diseases

Two rare but potentially deadly blood-clotting diseases, namely thrombotic thrombocytopenic purpura, or TTP, and hemolytic uremic syndrome, or HUS, show similar pathologies -- a multitude of painful blockages in small blood vessels that cause varying degrees of organ injury throughout the body. However, the two disorders have distinct biological mechanisms.

8 Sep 2019

First therapy indicated for treating adults with rare blood clotting disorder receives FDA approval

The U.S. Food and Drug Administration today approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening disorder that causes blood clotting.

7 Feb 2019

Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder

In proof-of-concept experiments, University of Alabama at Birmingham researchers have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP.

24 Sep 2018

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

University of Alabama at Birmingham researcher X. Long Zheng, M.D., Ph.D., has received a five-year, $2.5 million National Institutes of Health grant to study the pathogenesis of thrombotic microangiopathy, or TMA. In simple terms, this means looking for factors that cause or aid the onset of extensive microscopic clots in small blood vessels throughout the body. Though tiny, these spots can damage kidneys, heart and brain, and they can cause death.

29 Oct 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

23 Jul 2015

Study points to potential treatment for thrombotic thrombocytopenic purpura

A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of tiny blood vessels, formed after the patient's own immune system somehow inhibits an enzyme that is vital to control clotting.

23 Jul 2015

New ASH report outlines several models for 'systems-based clinical hematologist'

A report released today from the American Society of Hematology in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today’s rapidly changing U.S. health-care system.

9 Mar 2015

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

People hospitalized with certain rare blood cell disorders frequently receive a treatment that is associated with a two- to fivefold increase in death, according to a new study that reviewed hospital records nationwide. The study authors recommend that for these rare disorders, doctors should administer the treatment, a platelet transfusion, only in exceptional circumstances.

14 Jan 2015

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013